Market Cap
US$5.4b
Last Updated
2021/05/08 07:01 UTC
Data Sources
Company Financials +
Executive Summary
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Reasonable growth potential with mediocre balance sheet.
Similar Companies
Share Price & News
How has Nevro's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NVRO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: NVRO's weekly volatility (5%) has been stable over the past year.
Market Performance
7 Day Return
-9.6%
NVRO
-2.5%
US Medical Equipment
-0.3%
US Market
1 Year Return
25.1%
NVRO
33.9%
US Medical Equipment
50.2%
US Market
Return vs Industry: NVRO underperformed the US Medical Equipment industry which returned 33.9% over the past year.
Return vs Market: NVRO underperformed the US Market which returned 50.2% over the past year.
Shareholder returns
| NVRO | Industry | Market | |
|---|---|---|---|
| 7 Day | -9.6% | -2.5% | -0.3% |
| 30 Day | 7.2% | 4.2% | 2.2% |
| 90 Day | -11.7% | 1.8% | 3.8% |
| 1 Year | 25.1%25.1% | 34.9%33.9% | 52.7%50.2% |
| 3 Year | 103.7%103.7% | 73.1%69.0% | 63.4%53.1% |
| 5 Year | 146.5%146.5% | 154.8%136.3% | 129.6%104.0% |
Long-Term Price Volatility Vs. Market
How volatile is Nevro's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
Nevro Corp.'s (NYSE:NVRO) Shift From Loss To Profit2 weeks ago | Simply Wall St
Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?1 month ago | Simply Wall St
Have Insiders Been Selling Nevro Corp. (NYSE:NVRO) Shares?Valuation
Is Nevro undervalued compared to its fair value and its price relative to the market?
14.8x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: NVRO ($156.22) is trading above our estimate of fair value ($58.07)
Significantly Below Fair Value: NVRO is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: NVRO is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: NVRO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NVRO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NVRO is overvalued based on its PB Ratio (14.8x) compared to the US Medical Equipment industry average (4.7x).
Future Growth
How is Nevro forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
66.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NVRO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: NVRO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NVRO's is expected to become profitable in the next 3 years.
Revenue vs Market: NVRO's revenue (16.5% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: NVRO's revenue (16.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NVRO is forecast to be unprofitable in 3 years.
Past Performance
How has Nevro performed over the past 5 years?
-20.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NVRO is currently unprofitable.
Growing Profit Margin: NVRO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NVRO is unprofitable, and losses have increased over the past 5 years at a rate of 20.6% per year.
Accelerating Growth: Unable to compare NVRO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NVRO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.1%).
Return on Equity
High ROE: NVRO has a negative Return on Equity (-23.96%), as it is currently unprofitable.
Financial Health
How is Nevro's financial position?
Financial Position Analysis
Short Term Liabilities: NVRO's short term assets ($738.7M) exceed its short term liabilities ($246.4M).
Long Term Liabilities: NVRO's short term assets ($738.7M) exceed its long term liabilities ($163.1M).
Debt to Equity History and Analysis
Debt Level: NVRO's debt to equity ratio (86%) is considered high.
Reducing Debt: NVRO's debt to equity ratio has increased from 9.2% to 86% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NVRO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NVRO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Dividend
What is Nevro current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NVRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NVRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NVRO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NVRO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NVRO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.0yrs
Average management tenure
CEO
D. Grossman (60 yo)
2.17yrs
Tenure
US$8,989,919
Compensation
Mr. D. Keith Grossman serves as President, Chief Executive Officer and Director of Nevro Corp. since March 19, 2019 and has been its Chairman of the Board since May 20, 2019. He has been an Independent Dir...
CEO Compensation Analysis
Compensation vs Market: D.'s total compensation ($USD8.99M) is above average for companies of similar size in the US market ($USD6.51M).
Compensation vs Earnings: D.'s compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: NVRO's management team is considered experienced (2 years average tenure).
Board Members
Experienced Board: NVRO's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.
Top Shareholders
Company Information
Nevro Corp.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Nevro Corp.
- Ticker: NVRO
- Exchange: NYSE
- Founded: 2006
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$5.445b
- Shares outstanding: 34.78m
- Website: https://www.nevro.com
Number of Employees
Location
- Nevro Corp.
- 1800 Bridge Parkway
- Redwood City
- California
- 94065
- United States
Listings
Biography
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord sti...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/05/08 07:01 |
| End of Day Share Price | 2021/05/07 00:00 |
| Earnings | 2021/03/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.